Professional Advisory Services Inc. Sells 1,858 Shares of Stryker Corporation $SYK

Key Points

• Professional Advisory Services Inc. reduced its stake in Stryker Corporation by 3.3%, holding now 55,159 shares worth approximately $21.8 million.
• Insider transactions include Director Ronda E. Stryker selling 200,000 shares for $75.29 million, indicating a 5.84% decrease in her position.
• Stryker reported $3.13 earnings per share (EPS) for the last quarter, exceeding estimates, and set an EPS guidance of 13.400-13.600 for FY 2025.

Professional Advisory Services Inc. trimmed its holdings in shares of Stryker Corporation (NYSE:SYK - Free Report) by 3.3% during the 2nd quarter, according to its most recent disclosure with the Securities and Exchange Commission. The firm owned 55,159 shares of the medical technology company's stock after selling 1,858 shares during the period. Stryker makes up about 3.0% of Professional Advisory Services Inc.'s holdings, making the stock its 13th biggest position. Professional Advisory Services Inc.'s holdings in Stryker were worth $21,823,000 at the end of the most recent quarter.

Several other hedge funds also recently bought and sold shares of SYK. Capital A Wealth Management LLC acquired a new position in Stryker in the 4th quarter worth about $26,000. Goodman Advisory Group LLC acquired a new position in Stryker in the 1st quarter worth about $32,000. City Holding Co. increased its position in Stryker by 528.6% in the 1st quarter. City Holding Co. now owns 88 shares of the medical technology company's stock worth $33,000 after purchasing an additional 74 shares during the last quarter. Ransom Advisory Ltd bought a new stake in shares of Stryker during the 1st quarter worth about $37,000. Finally, Smallwood Wealth Investment Management LLC bought a new stake in shares of Stryker during the 1st quarter worth about $40,000. 77.09% of the stock is owned by institutional investors and hedge funds.

Insiders Place Their Bets

In other Stryker news, Director Ronda E. Stryker sold 200,000 shares of the stock in a transaction on Wednesday, August 6th. The stock was sold at an average price of $376.45, for a total value of $75,290,000.00. Following the transaction, the director directly owned 3,222,108 shares in the company, valued at approximately $1,212,962,556.60. This trade represents a 5.84% decrease in their position. The sale was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this hyperlink. Also, insider Viju Menon sold 500 shares of the stock in a transaction on Monday, August 25th. The shares were sold at an average price of $390.61, for a total value of $195,305.00. Following the completion of the transaction, the insider owned 12,511 shares in the company, valued at $4,886,921.71. The trade was a 3.84% decrease in their ownership of the stock. The disclosure for this sale can be found here. 5.20% of the stock is currently owned by company insiders.

Stryker Price Performance

SYK stock traded down $5.28 during midday trading on Tuesday, reaching $372.94. 983,699 shares of the company's stock traded hands, compared to its average volume of 1,393,045. The company has a 50-day simple moving average of $387.26 and a two-hundred day simple moving average of $379.05. Stryker Corporation has a 1-year low of $329.16 and a 1-year high of $406.19. The company has a market cap of $142.58 billion, a price-to-earnings ratio of 49.33, a PEG ratio of 2.71 and a beta of 0.93. The company has a quick ratio of 1.06, a current ratio of 1.78 and a debt-to-equity ratio of 0.70.

Stryker (NYSE:SYK - Get Free Report) last released its quarterly earnings results on Thursday, July 31st. The medical technology company reported $3.13 earnings per share for the quarter, beating analysts' consensus estimates of $3.07 by $0.06. The firm had revenue of $6.02 billion during the quarter, compared to analysts' expectations of $5.92 billion. Stryker had a return on equity of 23.94% and a net margin of 12.25%.The business's revenue was up 11.1% on a year-over-year basis. During the same period last year, the firm posted $2.81 EPS. Stryker has set its FY 2025 guidance at 13.400-13.600 EPS. On average, analysts anticipate that Stryker Corporation will post 13.47 earnings per share for the current year.

Stryker Dividend Announcement

The company also recently disclosed a quarterly dividend, which will be paid on Friday, October 31st. Shareholders of record on Tuesday, September 30th will be given a $0.84 dividend. This represents a $3.36 dividend on an annualized basis and a yield of 0.9%. The ex-dividend date is Tuesday, September 30th. Stryker's dividend payout ratio (DPR) is presently 44.50%.

Wall Street Analyst Weigh In

Several research firms have recently issued reports on SYK. BTIG Research reiterated a "buy" rating on shares of Stryker in a research note on Monday, July 14th. Evercore ISI upped their price target on Stryker from $390.00 to $415.00 and gave the stock an "outperform" rating in a research note on Tuesday, July 8th. Redburn Partners set a $420.00 price target on Stryker in a research note on Thursday, September 18th. Rothschild Redb upgraded Stryker to a "hold" rating in a research note on Thursday, September 18th. Finally, Needham & Company LLC upped their price target on Stryker from $442.00 to $448.00 and gave the stock a "buy" rating in a research note on Friday, August 1st. Fourteen equities research analysts have rated the stock with a Buy rating and six have assigned a Hold rating to the company. According to MarketBeat, the company currently has an average rating of "Moderate Buy" and an average target price of $430.33.

Stryker Profile

Stryker Corporation operates as a medical technology company. The company operates through two segments, MedSurg and Neurotechnology, and Orthopaedics and Spine. The Orthopaedics and Spine segment provides implants for use in total joint replacements, such as hip, knee and shoulder, and trauma and extremities surgeries.